ArticleAnnals of surgical oncology2017
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
Article in Annals of surgical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Characteristics and Treatment Patterns of Early Stage Melanoma: Results from a Multisite Chart Review.Drugs - real world outcomes · 2026Article
- Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?Annals of surgical oncology · 2026Article
- The Correlation between Plasma Circulating Tumor DNA and Radiographic Tumor Burden.The Journal of molecular diagnostics : JMD · 2024Review
- Stage IIA Cutaneous Melanoma: Do Regional Ultrasound and CT scan Improve Detection of Relapses? A Multicenter Retrospective Observational Study.Dermatology practical & conceptual · 2024Article
- Temporal Recurrence of Cutaneous Melanoma: Analysis of a Case Series.The Journal of clinical and aesthetic dermatology · 2023Article
- Patterns of Recurrence of Cutaneous Melanoma: A Literature Review.Dermatology practical & conceptual · 2023Review
- Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.Advances in therapy · 2023Article
- The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.Journal of translational medicine · 2023Article
- Pathway Alterations in Stage II/III Primary Melanoma.JCO precision oncology · 2023Article
- A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients.Frontiers in medicine · 2023Article
- Fifty years of progress in surgical oncology: Melanoma.Journal of surgical oncology · 2022Article
- Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts.Annals of surgical oncology · 2022Article
- Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Article
- Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.Current problems in surgery · 2022Review
- Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence.Acta dermato-venereologica · 2021Article
- Canadian Melanoma Conference Recommendations on High-Risk Melanoma Surveillance: A Report from the 14th Annual Canadian Melanoma Conference; Banff, Alberta; 20-22 February 2020.Current oncology (Toronto, Ont.) · 2021Article
- The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden.Cancers · 2021Article
- Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.Molecular diagnosis & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposePathologic stage II melanoma patients have variable outcomes when divided by substage. We hypothesized that an understanding of the patterns of initial relapse by substage will better inform follow-up guidelines.
methodsWe performed a retrospective review of 738 adult patients with pathologic stage II cutaneous melanoma treated at Memorial Sloan Kettering Cancer Center between 1993 and 2013. Clinical records were reviewed to determine time, location, and method of detection of initial relapse.
resultsAt a median follow-up of 52 months, 219 patients relapsed. Relapses were detected more frequently in higher substages. Initial relapses were most commonly local/in-transit for IIA and IIB and systemic for IIC. Lung and brain were the most frequent sites of systemic relapse. Patient-detection was the most common method of relapse detection (59%) in all substages. The 5-year cumulative incidence for patient-detected relapse was 13.6% for IIA, 18.9% for IIB, and 23.3% for IIC and for image-detected relapse was 3.4, 7.9, and 16.6%, respectively. The 5-year cumulative incidence for physician-detected relapse was less than 10% across all substages and leveled off at 3 years for stage IIA and IIB and 2 years for stage IIC.
conclusionsRelapses were most frequently patient-detected in all stage II substages, highlighting the importance of patient education and self-examination. The highest yield for routine imaging is in stage IIC patients during the first 4 years. Physician examination is unlikely to detect relapses beyond 3 years for stage IIA and IIB and beyond 2 years for stage IIC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.